Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
234 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2014', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Plaque Psoriasis (Psoriasis Vulgaris) Overview 9 Therapeutics Development 10 Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview 10 Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis 11 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 12 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 20 Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 24 Johnson & Johnson 24 Kyowa Hakko Kirin Co., Ltd. 25 Valeant Pharmaceuticals International, Inc. 26 Amgen Inc. 27 Celltrion, Inc. 28 Novartis AG 29 Biocon Limited 30 LEO Pharma A/S 31 Pfizer Inc. 32 UCB S.A. 33 Celgene Corporation 34 Idera Pharmaceuticals, Inc. 35 Almirall, S.A. 36 Protalix BioTherapeutics, Inc. 37 Biotie Therapies Corp. 38 R-Tech Ueno, Ltd. 39 Anacor Pharmaceuticals, Inc. 40 Circassia Holdings Ltd. 41 Coronado Biosciences, Inc. 42 TetraLogic Pharmaceuticals 43 Vascular Biogenics Ltd. 44 Invion Limited 45 ISDIN 46 Promius Pharma, LLC 47 Avesthagen Limited 48 Maruho Co., Ltd. 49 CalciMedica, Inc. 50 Biosidus S.A. 51 XBiotech USA, Inc. 52 Forward Pharma A/S 53 Delenex Therapeutics AG 54 Creabilis SA 55 Dermira Inc. 56 Kadmon Corporation, LLC 57 Cormorant Pharmaceuticals AB 58 Epirus Biopharmaceuticals, Inc. 59 AlphaMab Co., Ltd 60 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 secukinumab - Drug Profile 73 (betamethasone dipropionate + calcipotriene) - Drug Profile 77 infliximab biosimilar - Drug Profile 79 brodalumab - Drug Profile 81 tofacitinib - Drug Profile 83 apremilast - Drug Profile 87 pefcalcitol - Drug Profile 89 dimethyl fumarate - Drug Profile 90 infliximab biosimilar - Drug Profile 91 M-801801 - Drug Profile 92 adalimumab biosimilar - Drug Profile 93 DFD-01 - Drug Profile 94 M-8010 - Drug Profile 95 ASKP-1240 - Drug Profile 96 certolizumab pegol - Drug Profile 97 KD-025 - Drug Profile 103 CT-327 - Drug Profile 104 VB-201 - Drug Profile 106 LAS-41004 - Drug Profile 108 AN-2728 - Drug Profile 109 INV-103 - Drug Profile 111 DRM-02 - Drug Profile 113 CNDO-201 - Drug Profile 114 pefcalcitol - Drug Profile 116 DLX-105 - Drug Profile 117 RA-18C3 - Drug Profile 118 IDP-118 - Drug Profile 120 IMO-8400 - Drug Profile 121 MOL-4239 - Drug Profile 123 AM-001 - Drug Profile 124 DFD-06 - Drug Profile 125 HuMax-IL8 - Drug Profile 126 cyclosporine - Drug Profile 127 DLX-105 - Drug Profile 128 AVX-001 - Drug Profile 129 calcipotriene - Drug Profile 130 BTT-1023 - Drug Profile 131 guselkumab - Drug Profile 133 CIR-001 - Drug Profile 135 CM-2489 - Drug Profile 136 etanercept biosimilar - Drug Profile 138 LP-0058 - Drug Profile 139 SHP-141 - Drug Profile 140 LEO-35299 - Drug Profile 142 adalimumab biosimilar - Drug Profile 143 etanercept biosimilar - Drug Profile 144 RTU-1096 - Drug Profile 145 etanercept biosimilar - Drug Profile 146 adalimumab biosimilar - Drug Profile 147 etanercept biosimilar - Drug Profile 148 ustekinumab biosimilar - Drug Profile 149 etanercept biosimilar - Drug Profile 150 adalimumab biosimilar - Drug Profile 151 adalimumab biosimilar - Drug Profile 152 adalimumab biosimilar - Drug Profile 153 adalimumab biosimilar - Drug Profile 154 etanercept biosimilar - Drug Profile 155 Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates 156 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 214 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 215 Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 216 Featured News & Press Releases 216 Appendix 229 Methodology 229 Coverage 229 Secondary Research 229 Primary Research 229 Expert Panel Validation 229 Contact Us 230 Disclaimer 230
List of Tables Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2014 14 Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Comparative Analysis by Unknown Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Development by Companies, H2 2014 (Contd..2) 26 Products under Development by Companies, H2 2014 (Contd..3) 27 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2014 28 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 29 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 30 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2014 31 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H2 2014 32 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2014 33 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2014 34 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2014 35 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2014 36 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2014 37 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H2 2014 38 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 39 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2014 40 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 41 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biotie Therapies Corp., H2 2014 42 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H2 2014 43 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 44 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Circassia Holdings Ltd., H2 2014 45 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coronado Biosciences, Inc., H2 2014 46 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H2 2014 47 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Vascular Biogenics Ltd., H2 2014 48 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H2 2014 49 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by ISDIN, H2 2014 50 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2014 51 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H2 2014 52 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2014 53 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2014 54 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biosidus S.A., H2 2014 55 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H2 2014 56 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2014 57 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H2 2014 58 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H2 2014 59 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H2 2014 60 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2014 61 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cormorant Pharmaceuticals AB, H2 2014 62 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 63 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AlphaMab Co., Ltd, H2 2014 64 Assessment by Monotherapy Products, H2 2014 65 Assessment by Combination Products, H2 2014 66 Number of Products by Stage and Target, H2 2014 69 Number of Products by Stage and Mechanism of Action, H2 2014 72 Number of Products by Stage and Route of Administration, H2 2014 74 Number of Products by Stage and Molecule Type, H2 2014 76 Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H2 2014 160 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2014 218 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2014 219
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
